Overview

Cangrelor to Clopidogrel or Prasugrel Transition Study

Status:
Completed
Trial end date:
2014-01-20
Target enrollment:
Participant gender:
Summary
There are two separate objectives in this study: 1. To demonstrate the pharmacodynamic (PD) profile when participants treated with cangrelor are switched to oral prasugrel 60 mg administered 30 minutes (min) after cangrelor infusion is discontinued 2. To demonstrate the PD profile when participants treated with cangrelor are switched to oral clopidogrel 600 mg administered during or immediately after cangrelor infusion.
Phase:
Phase 2
Details
Lead Sponsor:
The Medicines Company
Treatments:
Cangrelor
Clopidogrel
Prasugrel Hydrochloride
Ticlopidine